SPLASH Trial Results Reinforce Benefits of RLT for mCRPC After Progression on ARPI

By Oliver Sartor, MD - Last Updated: October 1, 2024

At ESMO Congress 2024, Oliver Sartor, MD, Mayo Clinic, gave an overview of the SPLASH trial on the use of PSMA-targeted therapies for patients with prostate cancer.

He discusses how Lu-PNT compares to ARPI, and what clinicians should consider when choosing the former treatment for patients.

ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC

Emily MenendezRLT | March 7, 2025

Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.

TALAPRO-2 and First-Line mCRPC Treatment: Insights on OS Benefits and Treatment Sequencing

Alan Tan, MDCRPC | March 5, 2025

Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.

Mevrometostat With Enzalutamide: Better Outcomes Compared With Enzalutamide Monotherapy for mCRPC

Emily MenendezCRPC | February 25, 2025

The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.

Final TALAPRO-2 Analysis: Talazoparib Plus Enzalutamide Significantly Improves Survival in HRR-Deficient mCRPC

Brandon TwyfordCRPC | February 21, 2025

Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.

Real-World Outcomes of Lu-PSMA-617 in mCRPC

Jordan Ciuro, MDCRPC | February 14, 2025

New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.

SPLASH Trial Results Reinforce Benefits of RLT for mCRPC After Progression on ARPI

Related Posts